Pranlukast hydrate in the treatment of pediatric bronchial asthma
Shigemi Yoshihara Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan Abstract: Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatr...
Saved in:
Main Author: | Yoshihara S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PEDIATRIC BRONCHIAL ASTHMA: MODERN TREATMENT ASPECTS
by: O.V. Zaitseva, et al.
Published: (2011) -
PEDIATRIC BRONCHIAL ASTHMA: MODERN TREATMENT ASPECTS
by: O.V. Zaitseva, et al.
Published: (2011) -
Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization
by: Ha ES, et al.
Published: (2015) -
Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells
by: Velázquez-Quesada I, et al.
Published: (2020) -
Asthma control test (ACT) and bronchial challenge with exercise in pediatric asthma.
by: Salvatore eTripodi, et al.
Published: (2016)